Drugs / GT202
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05238818 | Mar 2022 → Jan 2024 | female reproductive organ cancer | XinWu | Unknown | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-11-11 | Grit Biotechnology | Grit Bio（沙砾生物） to Present Next-Gen TIL Therapy Program GT202 at AACR 2022 gritbio.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GT202 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05238818 ↗ |
| Modality | Cell therapy | “Autologous Tumor Infiltrating Lymphocyte Injection (GT202)” NCT05238818 ↗ |